痛風治療薬の世界市場分析:薬の種類別(非ステロイド性抗炎症薬[NSAIDs]、コルチコステロイド、コルヒチン、尿酸塩低下薬)、病気の状態別(急性痛風、慢性痛風)、セグメント予測、2014-2025

【英語タイトル】Gout Therapeutics Market Analysis By Drug Class (Nonsteroidal Anti-inflammatory Drugs [NSAIDs], Corticosteroids, Colchicine, Urate-Lowering Agents), By Disease Condition (Acute Gout, Chronic Gout), And Segment Forecasts, 2014-2025

Grand View Researchが出版した調査資料(GVIEW707374)・商品コード:GVIEW707374
・発行会社(調査会社):Grand View Research
・発行日:2017年3月7日
・ページ数:100
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:医療
◆販売価格オプション(消費税別)
Single UserUSD4,950 ⇒換算¥539,550見積依頼/購入/質問フォーム
Multi UserUSD7,950 ⇒換算¥866,550見積依頼/購入/質問フォーム
Global/corporate LicenseUSD9,950 ⇒換算¥1,084,550見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
本調査レポートでは、痛風治療薬の世界市場について調査・分析し、痛風治療薬の世界市場動向、痛風治療薬の世界市場規模、市場予測、セグメント別痛風治療薬市場分析、主要地域別市場規模、競争状況、関連企業情報などを含め、以下の構成でお届け致します。
【レポートの概要】

The global gout therapeutics market is expected to reach a value of USD 8.3 billion By 2025, based on a new report by Grand View Research, Inc. The gout therapeutics market is anticipated to witness significant growth during the forecast period. This can be attributed to the introduction of major urate-lowering agents, approval of effective biologics, and increasing number of patients suffering from chronic gout.
In December 2015, AstraZeneca’s product, Zurampic (lesinurad), in combination with xanthine oxidase inhibitor (XOI) received an approval from the U. S. FDA to treat gout. Later in February 2016, the European Commission approved the drug throughout the European Union (EU). Hence, introduction of urate-lowering agents is expected to drive the market.

Introduction of biologics to treat gout and increasing adoption of newer therapies further help propel the industry. For instance, in March 2013, Novartis received an EU approval for the product, Ilaris, for use in the treatment of patients suffering from gouty arthritis.

Further key findings from the study suggest:

Nonsteroidal Anti-inflammatory Agents (NSAIDs) accounted for the highest share of the market in 2015, which can be credited to highest penetration, higher demand due to low cost, and efficient pain relief.

Urate-lowering agents segment is expected to grow at the highest rate over the coming years. Expected entry of various new drugs, increasing adoption of drugs, and growing investment by key players for development of these agents are likely to drive the segment.

Chronic gout dominated in 2015 and is expected to maintain its dominance during the forecast period. Approval of new drugs to treat chronic gout and long-term expenditure for treatment are the key factors responsible to propel the industry.

NSAIDs, colchicine, and corticosteroids are majorly used to treat acute gout, and urate-lowering agents are utilized in chronic gout treatment in combination with NSAIDs or Colchicine.

Geographically, North America dominated the overall industry in 2015. This is attributed to higher adoption of the newer & expensive treatments and rising awareness about arthritic conditions.

Asia Pacific is expected to witness highest growth during the forecast period due to growing awareness and increasing healthcare expenditure. Furthermore, growing investment in the region by key players is likely to boost the regional growth.

Some of the key players are Takeda Pharmaceutical Company Ltd.; Novartis AG; Savient Pharmaceuticals; AstraZeneca plc; GlaxoSmithKline plc; Merck& Co. Inc.; Teijin Pharma Ltd.; and Regeneron Pharmaceuticals.

【レポートの目次】

Table of Content

Chapter 1 Research Methodology
1.1 Information Procurement
1.2 Data Analysis
Chapter 2 Executive Summary
2.1 Market Snapshot
Chapter 3 Gout Therapeutics Market Variables, Trends & Scope
3.1 Market Segmentation and Scope
3.1.1 Market driver analysis
3.1.1.1 Introduction of urate-lowering agents
3.1.1.2 Rising prevalence of gout
3.1.2 Market restraint analysis
3.1.2.1 Competition from generic drugs
3.1.2.2 High cost of recently launched drugs
3.2 Penetration & Growth Prospects Mapping
3.3 Gout Therapeutics Market – PESTLE Analysis
3.4 Industry Analysis – Porter’s
3.5 Gout Therapeutics Competitive Scenario
3.5.1 Competitive landscape: Market position analysis (based on product portfolio, regional presence and strategic initiatives)
Chapter 4 Gout Therapeutics: Drug Class Estimates & Trend Analysis
4.1 Global Gout Therapeutics Market: Drug Class Movement Analysis
4.2 NSAIDs
4.2.1 NSAIDs market estimates and forecasts, 2014 – 2025 (USD Million)
4.3 Corticosteroids
4.3.1 Corticosteroids market estimates and forecasts, 2014 – 2025 (USD Million)
4.4 Colchicine
4.4.1 Colchicine market estimates and forecasts, 2014 – 2025 (USD Million)
4.5 Urate-Lowering Agents
4.5.1 Urate-lowering agents market estimates and forecasts, 2014 – 2025 (USD Million)
Chapter 5 Gout Therapeutics: Disease Condition Estimates & Trend Analysis
5.1 Global Gout Therapeutics Market: Disease Condition Movement Analysis
5.2 Acute Gout
5.2.1 Acute market estimates and forecasts, 2014 – 2025 (USD Million)
5.3 Chronic Gout
5.3.1 Chronic gout market estimates and forecasts, 2014 – 2025 (USD Million)
Chapter 6 Gout Therapeutics: Regional Estimates & Trend Analysis
6.1 Regional Movement Analysis & Market Share, 2015 & 2025
6.2 North America
6.2.1 North America gout therapeutics market, by drug class, 2014 – 2025 (USD Million)
6.2.2 North America gout therapeuticsmarket, by disease condition , 2014 – 2025 (USD Million)
6.2.3 U.S.
6.2.3.1 U.S. gout therapeutics market, by drug class, 2014 – 2025 (USD Million)
6.2.3.2 U.S. gout therapeuticsmarket, by disease condition , 2014 – 2025 (USD Million)
6.2.4 Canada
6.2.4.1 Canada gout therapeuticsmarket, by drug class, 2014 – 2025 (USD Million)
6.2.4.2 Canadagout therapeuticsmarket, by disease condition , 2014 – 2025 (USD Million)
6.3 Europe
6.3.1 Europe gout therapeuticsmarket, by drug class, 2014 – 2025 (USD Million)
6.3.2 Europe gout therapeuticsmarket, by disease condition , 2014 – 2025 (USD Million)
6.3.3 Germany
6.3.3.1 Germany gout therapeuticsmarket, by drug class, 2014 – 2025 (USD Million)
6.3.3.2 Germanygout therapeuticsmarket, by disease condition , 2014 – 2025 (USD Million)
6.3.4 UK
6.3.4.1 UK gout therapeuticsmarket, by drug class, 2014 – 2025 (USD Million)
6.3.4.2 UK gout therapeuticsmarket, by disease condition , 2014 – 2025 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific gout therapeuticsmarket, by drug class, 2014 – 2025 (USD Million)
6.4.2 Asia Pacific gout therapeuticsmarket, by disease condition , 2014 – 2025 (USD Million)
6.4.3 Japan
6.4.3.1 Japan gout therapeuticsmarket, by drug class, 2014 – 2025 (USD Million)
6.4.3.2 Japan gout therapeuticsmarket, by disease condition , 2014 – 2025 (USD Million)
6.4.5 China
6.4.5.1 China gout therapeuticsmarket, by drug class, 2014 – 2025 (USD Million)
6.4.5.2 China gout therapeuticsmarket, by disease condition , 2014 – 2025 (USD Million)
6.5 Latin America
6.5.1 Latin America gout therapeuticsmarket, by drug class, 2014 – 2025 (USD Million)
6.5.2 Latin America gout therapeuticsmarket, by disease condition , 2014 – 2025 (USD Million)
6.5.3 Brazil
6.5.3.1 Brazil gout therapeuticsmarket, by drug class, 2014 – 2025 (USD Million)
6.5.3.2 Brazilgout therapeuticsmarket, by disease condition , 2014 – 2025 (USD Million)
6.5.4 Mexico
6.5.4.1 Mexicogout therapeuticsmarket, by drug class, 2014 – 2025 (USD Million)
6.5.4.2 Mexicogout therapeuticsmarket, by disease condition , 2014 – 2025 (USD Million)
6.6 MEA
6.6.1 MEA gout therapeuticsmarket, by drug class, 2014 – 2025 (USD Million)
6.6.2 MEA gout therapeuticsmarket, by disease condition , 2014 – 2025 (USD Million)
6.6.3 South Africa
6.6.3.1 South Africa gout therapeuticsmarket, by drug class, 2014 – 2025 (USD Million)
6.6.3.2 South Africagout therapeuticsmarket, by disease condition , 2014 – 2025 (USD Million)
Chapter 7 Competitive Landscape
7.1 Takeda Pharmaceutical Company Ltd.
7.1.1 Company overview
7.1.2 Financial performance
7.1.3 Product benchmarking
7.1.4 Strategic initiatives
7.2 Novartis
7.2.1 Company overview
7.2.2 Financial performance
7.2.3 Product benchmarking
7.2.4 Strategic initiatives
7.3 Savient Pharmaceuticals
7.3.1 Company overview
7.3.2 Financial performance
7.3.3 Product benchmarking
7.3.4 Strategic initiatives
7.4 Regeneron Pharmaceuticals
7.4.1 Company overview
7.4.2 Financial performance
7.4.3 Product benchmarking
7.4.4 Strategic initiatives
7.5 AstraZeneca plc
7.5.1 Company overview
7.5.2 Financial performance
7.5.3 Product benchmarking
7.5.4 Strategic initiatives
7.6 Horizon Pharma plc
7.6.1 Company overview
7.6.2 Financial performance
7.6.3 Product benchmarking
7.6.4 Strategic Initiatives
7.7 Boehringer Ingelheim
7.7.1 Company overview
7.7.2 Financial performance
7.7.3 Product benchmarking
7.7.4 Strategic initiatives
7.8 Merck & Co. Inc
7.8.1 Company overview
7.8.2 Financial performance
7.8.3 Product benchmarking
7.8.4 Strategic initiatives
7.9 Teijin Pharma Ltd
7.9.1 Company overview
7.9.2 Financial performance
7.9.3 Product benchmarking
7.9.4 Strategic initiatives
7.10 GlaxoSmithKline plc
7.10.1 Company overview
7.10.2 Financial performance
7.10.3 Product benchmarking
7.10.4 Strategic initiatives

List of Figures

FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & Forecasting
FIG. 6 QFD modeling for market share assessment
FIG. 7 Market summary
FIG. 8 Market trends & outlook
FIG. 9 Market segmentation & scope
FIG. 10 Market driver relevance analysis (Current & future impact)
FIG. 11 Market restraint relevance analysis (Current & future impact)
FIG. 12 Penetration & growth prospect mapping
FIG. 13 Gout therapeutics market - PESTLE analysis
FIG. 14 Porter’s Five Forces Analysis
FIG. 15 Gout therapeutics market outlook key takeaways
FIG. 16 Gout therapeutics market: drug class movement analysis
FIG. 17 Global gout therapeutics market, by drug class, 2014 - 2025 (USD Million)
FIG. 18 Global gout therapeutics market, 2014 - 2025 (USD Million)
FIG. 19 Global NSAIDs market, 2014 - 2025 (USD Million)
FIG. 20 Global corticosteroids market, 2014 - 2025 (USD Million)
FIG. 21 Global colchicine market, 2014 - 2025 (USD Million)
FIG. 22 Global urate-lowering agents market, 2014 - 2025 (USD Million)
FIG. 23 Global gout therapeutics market: disease condition movement analysis
FIG. 24 Global gout therapeutics market, by disease condition, 2014 - 2025 (USD Million)
FIG. 25 Global acute gout market, 2014 - 2025 (USD Million)
FIG. 26 Global chronic gout market, 2014 - 2025 (USD Million)
FIG. 27 Regional market: Key takeaways
FIG. 28 Gout therapeutics market regional outlook, 2015 & 2024
FIG. 29 North America gout therapeutics market, 2014 - 2025 (USD Million)
FIG. 30 U.S. gout therapeutics market, 2014 - 2025 (USD Million)
FIG. 31 Canada gout therapeutics market, 2014 - 2025 (USD Million)
FIG. 32 Europe gout therapeutics market, 2014 - 2025 (USD Million)
FIG. 33 Germany gout therapeutics market, 2014 - 2025 (USD Million)
FIG. 34 UK gout therapeutics market, 2014 - 2025 (USD Million)
FIG. 35 Asia Pacific gout therapeutics market, 2014 - 2025 (USD Million)
FIG. 36 Japan gout therapeutics market, 2014 - 2025 (USD Million)
FIG. 37 China gout therapeutics market, 2014 - 2025 (USD Million)
FIG. 38 Latin America gout therapeutics market, 2014 - 2025 (USD Million)
FIG. 39 Brazil gout therapeutics market, 2014 - 2025 (USD Million)
FIG. 40 Mexico gout therapeutics market, 2014 - 2025 (USD Million)
FIG. 41 Middle East Africa gout therapeutics market, 2014 - 2025 (USD Million)
FIG. 42 South Africa gout therapeutics market, 2014 - 2025 (USD Million)
FIG. 43 Strategy frameworks

List of Tables

TABLE 1 Gout therapeutics market - global market current and forecast by regions (2015 - 2024) in (USD Million)
TABLE 2 North America gout therapeutics market estimates and forecasts, by country, 2014 - 2025 (USD Million)
TABLE 3 North America gout therapeutics market estimates and forecasts, by drug class, 2014 - 2025 (USD Million)
TABLE 4 North America gout therapeutics market estimates and forecasts, by disease condition, 2014 - 2025 (USD Million)
TABLE 5 U.S. gout therapeutics market estimates and forecasts, by drug class, 2014 - 2025 (USD Million)
TABLE 6 U.S. gout therapeutics market estimates and forecasts, by disease condition, 2014 - 2025 (USD Million)
TABLE 7 Canada gout therapeutics market estimates and forecasts, by drug class, 2014 - 2025 (USD Million)
TABLE 8 Canada gout therapeutics market estimates and forecasts, by disease condition, 2014 - 2025 (USD Million)
TABLE 9 Europe gout therapeutics market estimates and forecasts, by country, 2014 - 2025 (USD Million)
TABLE 10 Europe gout therapeutics market estimates and forecasts, by drug class, 2014 - 2025 (USD Million)
TABLE 11 Europe gout therapeutics market estimates and forecasts, by disease condition, 2014 - 2025 (USD Million)
TABLE 12 UK gout therapeutics market estimates and forecasts, by drug class, 2014 - 2025 (USD Million)
TABLE 13 UK gout therapeutics market estimates and forecasts, by disease condition, 2014 - 2025 (USD Million)
TABLE 14 Germany gout therapeutics market estimates and forecasts, by drug class, 2014 - 2025 (USD Million)
TABLE 15 Germany gout therapeutics market estimates and forecasts, by disease condition, 2014 - 2025 (USD Million)
TABLE 16 Asia Pacific gout therapeutics market estimates and forecasts, by region, 2014 - 2025 (USD Million)
TABLE 17 Asia Pacific gout therapeutics market estimates and forecasts, by drug class, 2014 - 2025 (USD Million)
TABLE 18 Asia Pacific gout therapeutics market estimates and forecasts, by disease condition, 2014 - 2025 (USD Million)
TABLE 19 Japan gout therapeutics market estimates and forecasts, by drug class, 2014 - 2025 (USD Million)
TABLE 20 Japan gout therapeutics market estimates and forecasts, by disease condition, 2014 - 2025 (USD Million)
TABLE 21 China gout therapeutics market estimates and forecasts, by drug class, 2014 - 2025 (USD Million)
TABLE 22 China gout therapeutics market estimates and forecasts, by disease condition, 2014 - 2025 (USD Million)
TABLE 23 Latin America gout therapeutics market estimates and forecasts, by country, 2014 - 2025 (USD Million)
TABLE 24 Latin America gout therapeutics market estimates and forecasts, by drug class, 2014 - 2025 (USD Million)
TABLE 25 Latin America gout therapeutics market estimates and forecasts, by disease condition, 2014 - 2025 (USD Million)
TABLE 26 Brazil gout therapeutics market estimates and forecasts, by drug class, 2014 - 2025 (USD Million)
TABLE 27 Brazil gout therapeutics market estimates and forecasts, by disease condition, 2014 - 2025 (USD Million)
TABLE 28 Mexico gout therapeutics market estimates and forecasts, by drug class, 2014 - 2025 (USD Million)
TABLE 29 Mexico gout therapeutics market estimates and forecasts, by disease condition, 2014 - 2025 (USD Million)
TABLE 30 MEA gout therapeutics market estimates and forecasts, by country, 2014 - 2025 (USD Million)
TABLE 31 MEA gout therapeutics market estimates and forecasts, by drug class, 2014 - 2025 (USD Million)
TABLE 32 MEA gout therapeutics market estimates and forecasts, by disease condition, 2014 - 2025 (USD Million)
TABLE 33 South Africa gout therapeutics market estimates and forecasts, by drug class, 2014 - 2025 (USD Million)
TABLE 34 South Africa gout therapeutics market estimates and forecasts, by disease condition, 2014 - 2025 (USD Million)

★調査レポート[痛風治療薬の世界市場分析:薬の種類別(非ステロイド性抗炎症薬[NSAIDs]、コルチコステロイド、コルヒチン、尿酸塩低下薬)、病気の状態別(急性痛風、慢性痛風)、セグメント予測、2014-2025] (コード:GVIEW707374)販売に関する免責事項を必ずご確認ください。
★調査レポート[痛風治療薬の世界市場分析:薬の種類別(非ステロイド性抗炎症薬[NSAIDs]、コルチコステロイド、コルヒチン、尿酸塩低下薬)、病気の状態別(急性痛風、慢性痛風)、セグメント予測、2014-2025]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆